Subcutaneous amivantamab plus chemotherapy offers an equally effective treatment for EGFR exon 20 insertion non–small cell lung cancer (NSCLC), mirroring PAPILLON results of the intravenous formulation, explained Sun Lim Min, MD, PhD.
Sun Lim Min, MD, PhD
Advertisement
Sun Min Lim, MD, PhD, works in the Division of Medical Oncology in the Department of Internal Medicine at Yonsei University College of Medicine in Seoul, South Korea.
Articles by Sun Lim Min, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Ongoing COVID-19 Circulation Linked to Increases in Health-Related Work Absences, Workforce Exits
2
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
3
After Narrow Miss in Phase 3 Study, IO Biotech Ponders Next Steps for Immune-Modulatory, Off-the-Shelf Cancer Vaccine
4
Many US Health Care Workers Face Poverty, Food Insecurity, and Housing Instability
5
